Teva Pharmaceutical Industries Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Teva Pharmaceutical Industries ha aumentado sus beneficios a una tasa media anual de 17.9%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 1.2%. Los ingresos han ido disminuyendo a una tasa media de 1.5% al año.
Información clave
17.9%
Tasa de crecimiento de los beneficios
18.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | -1.5% |
| Rentabilidad financiera | -19.1% |
| Margen neto | -5.7% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Teva Pharmaceutical Industries. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 16,772 | -959 | 3,652 | 978 |
| 30 Jun 24 | 16,290 | -453 | 3,573 | 991 |
| 31 Mar 24 | 16,004 | -478 | 3,542 | 961 |
| 31 Dec 23 | 15,846 | -559 | 3,498 | 953 |
| 30 Sep 23 | 15,273 | -2,336 | 3,433 | 936 |
| 30 Jun 23 | 15,017 | -2,350 | 3,409 | 858 |
| 31 Mar 23 | 14,925 | -1,711 | 3,407 | 847 |
| 31 Dec 22 | 14,925 | -2,446 | 3,445 | 838 |
| 30 Sep 22 | 15,141 | -1,291 | 3,516 | 872 |
| 30 Jun 22 | 15,433 | -1,054 | 3,583 | 919 |
| 31 Mar 22 | 15,557 | -615 | 3,533 | 938 |
| 31 Dec 21 | 15,878 | 417 | 3,528 | 967 |
| 30 Sep 21 | 16,231 | 726 | 3,630 | 1,016 |
| 30 Jun 21 | 16,324 | -3,915 | 3,626 | 1,052 |
| 31 Mar 21 | 16,284 | -3,982 | 3,629 | 1,030 |
| 31 Dec 20 | 16,659 | -3,990 | 3,671 | 997 |
| 30 Sep 20 | 16,673 | -4,031 | 3,686 | 936 |
| 30 Jun 20 | 16,788 | 4 | 3,681 | 919 |
| 31 Mar 20 | 17,095 | -825 | 3,783 | 970 |
| 31 Dec 19 | 16,887 | -999 | 3,806 | 1,010 |
| 30 Sep 19 | 16,396 | -4,048 | 3,922 | 1,073 |
| 30 Jun 19 | 16,831 | -4,007 | 4,051 | 1,143 |
| 31 Mar 19 | 17,355 | -3,559 | 4,087 | 1,157 |
| 31 Dec 18 | 18,271 | -2,399 | 4,214 | 1,213 |
| 30 Sep 18 | 19,693 | -11,059 | 4,073 | 1,264 |
| 30 Jun 18 | 20,781 | -10,256 | 4,280 | 1,484 |
| 31 Mar 18 | 21,800 | -16,050 | 4,589 | 1,663 |
| 31 Dec 17 | 21,853 | -16,525 | 4,846 | 1,778 |
| 30 Sep 17 | 23,479 | -5,963 | 5,335 | 2,116 |
| 30 Jun 17 | 23,425 | -6,145 | 5,370 | 2,248 |
| 31 Mar 17 | 22,743 | 78 | 5,326 | 2,154 |
| 31 Dec 16 | 21,903 | 68 | 4,973 | 2,077 |
| 30 Sep 16 | 20,292 | 1,591 | 4,863 | 1,873 |
| 30 Jun 16 | 19,552 | 1,346 | 4,709 | 1,571 |
| 31 Mar 16 | 19,480 | 1,697 | 4,631 | 1,582 |
| 31 Dec 15 | 19,652 | 1,573 | 4,838 | 1,525 |
| 30 Sep 15 | 19,939 | 1,775 | 4,836 | 1,458 |
| 30 Jun 15 | 20,174 | 2,548 | 4,983 | 1,509 |
| 31 Mar 15 | 20,253 | 2,757 | 5,021 | 1,467 |
| 31 Dec 14 | 20,272 | 3,055 | 5,078 | 1,488 |
| 30 Sep 14 | 20,534 | 2,748 | 5,200 | 1,520 |
| 30 Jun 14 | 20,535 | 2,583 | 5,225 | 1,456 |
| 31 Mar 14 | 20,414 | 1,383 | 5,303 | 1,451 |
| 31 Dec 13 | 20,314 | 1,269 | 5,319 | 1,427 |
Ingresos de calidad: TEVA actualmente no es rentable.
Margen de beneficios creciente: TEVA actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: TEVA no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 17.9% por año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de TEVA en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: TEVA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).
Rentabilidad financiera
Alta ROE: TEVA tiene una rentabilidad financiera negativa (-19.06%), ya que actualmente no es rentable.